NHS Branded Medicines Tranche Framework for London and South of England
Reference ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c · NHS England
Awarded to Sun Pharma UK Ltd and 28 others. Estimated value: £380,950,720.
Interested in tenders like this? Get the next tenders like this one published in the United Kingdom by email. Free, no card needed.
Amounts and figures
Description
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Awards
| Awarded to | Amount | Date |
|---|---|---|
| Sun Pharma UK Ltd | £380,950,720 | 22 July 2024 |
| Merck Sharpe & Dohme (UK) Limited | — | 22 July 2024 |
| Thornton and Ross Ltd | — | 22 July 2024 |
| AstraZeneca | — | 22 July 2024 |
| Janssen-Cilag Ltd | — | 22 July 2024 |
| Organon Pharmaceuticals UK Ltd | — | 22 July 2024 |
| Celltrion Healthcare United Kingdom Limited | — | 22 July 2024 |
| GlaxoSmithKline UK Limited | — | 22 July 2024 |
| Takeda UK Ltd | — | 22 July 2024 |
| Biogen | — | 22 July 2024 |
Official publications
| Medium | Reference | Date |
|---|---|---|
| FTS | 5804a973-6494-40b3-8ef1-7809f1927694-778994 | 20 August 2024 |
| Contracts Finder | 5804a973-6494-40b3-8ef1-7809f1927694-778994 | 20 August 2024 |
Other tenders from NHS England
See the buyer →- NHS Framework Agreement for Branded Medicines - Proprietary Category Tender - 1st May 2024 Published: 11 November 2024
- NHS National Framework for Transition products commencing 1 February 2025 Published: 14 October 2024
- NHS National Framework for Transition products commencing 1 October 2024 Published: 23 July 2024
- NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024 Published: 1 May 2024
- CM/PHR/23/5701- NHS National Framework for Natalizumab-February 2024 Published: 2 February 2024
- NHS National Framework Agreement for the supply of Eculizumab - 1 Feb 2024 Published: 2 February 2024
Similar open tenders
Frequently asked questions
- What is the deadline to bid for this tender?
- The submission deadline is 5 April 2024, 13:00. Check the official source, as dates can be modified.
- What is the estimated value of this tender?
- The estimated value published by the buyer is £380,950,720.
- Who is the buyer of this tender?
- The contracting authority is NHS England (United Kingdom).
- How can I bid for public tenders in the United Kingdom?
- Bids are submitted through the official public procurement portal in the United Kingdom. El Vínculo helps you find tenders and analyse their documents; submission always happens at the official source.
How can I find out about similar tenders when they are published?
Create an account at el-vinculo.com and we give you a free month and set up your company's filters — contract type, CPV codes, value and territory — so you are the first to know when new tenders like this one come out in the United Kingdom. We email you as soon as one matching your profile is published, with the whole deadline ahead to prepare the bid.
Public tenders by region
Create a free account and receive new public tenders published in the United Kingdom that match your business, every day.